Guard Therapeutics International AB (publ) (GUARD.ST)
- Previous Close
15.55 - Open
15.40 - Bid 15.00 x --
- Ask 15.25 x --
- Day's Range
14.80 - 15.60 - 52 Week Range
11.85 - 39.80 - Volume
56,253 - Avg. Volume
19,692 - Market Cap (intraday)
307.556M - Beta (5Y Monthly) -0.26
- PE Ratio (TTM)
-- - EPS (TTM)
-8.27 - Earnings Date May 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
52.25
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
guardtherapeutics.comRecent News: GUARD.ST
View MorePerformance Overview: GUARD.ST
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GUARD.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GUARD.ST
View MoreValuation Measures
Market Cap
307.56M
Enterprise Value
253.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
8.10
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-88.89%
Return on Equity (ttm)
-183.51%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-96.07M
Diluted EPS (ttm)
-8.27
Balance Sheet and Cash Flow
Total Cash (mrq)
54.19M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-59.24M